Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics, Inc. - Common Stock
(NQ:
VTGN
)
0.7928
-3.5672 (-81.82%)
Streaming Delayed Price
Updated: 11:58 AM EST, Dec 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
April 17, 2025
From
Vistagen
Via
Business Wire
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
March 19, 2025
From
Vistagen
Via
Business Wire
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
March 04, 2025
From
Vistagen
Via
Business Wire
Earnings Scheduled For February 13, 2025
↗
February 13, 2025
Via
Benzinga
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
February 20, 2025
From
Vistagen
Via
Business Wire
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
February 13, 2025
From
Vistagen
Via
Business Wire
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
February 06, 2025
From
Vistagen
Via
Business Wire
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
February 05, 2025
From
Vistagen
Via
Business Wire
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
January 14, 2025
From
Vistagen
Via
Business Wire
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
January 10, 2025
From
Vistagen
Via
Business Wire
Vistagen to Present at the Stifel 2024 Healthcare Conference
November 14, 2024
From
Vistagen
Via
Business Wire
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
November 07, 2024
From
Vistagen
Via
Business Wire
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
November 05, 2024
From
Vistagen
Via
Business Wire
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
November 01, 2024
From
Vistagen
Via
Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Joint Ceremony to Ring Nasdaq Closing Bell in Honor of World Mental Health Day
October 09, 2024
Via
Investor Brand Network
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
October 09, 2024
From
Vistagen
Via
Business Wire
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 23, 2024
From
Vistagen
Via
Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report
August 14, 2024
Via
Investor Brand Network
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025
↗
August 13, 2024
VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.
Via
InvestorPlace
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
August 13, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2025 Results, Conference Call
August 06, 2024
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
August 06, 2024
From
Vistagen
Via
Business Wire
3 Stocks Under $15 That Could Make You a Millionaire
↗
July 26, 2024
Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying.
Via
InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Awarded New Patents from Four Countries to Broaden Global PH80 IP Portfolio
July 09, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 09, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Receives Mental Health America’s Highest Honor
June 27, 2024
Via
Investor Brand Network
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
June 27, 2024
From
Vistagen
Via
Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update
June 12, 2024
Via
Investor Brand Network
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024
↗
June 12, 2024
VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via
InvestorPlace
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
June 11, 2024
From
Vistagen
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today